Treatment of Hepatitis C in Children
- 166 Downloads
Purpose of Review
The aim of this study is to summarize the state of treatment of hepatitis C virus (HCV) infection in children.
The 100 articles on HCV in children from 2011 to 2016 contained only one report of a trial with direct acting antiviral agents (DAAs) and none of these agents are yet FDA-approved for children. Thus, we will focus on issues critical to the understanding of the problem of HCV in the pediatric age group including global epidemiology and natural history, as well as results of treatment with the only agents currently FDA-approved for pediatric use: pegylated interferon alpha 2a or 2b plus ribavirin. In addition, the pediatric trials with DAAs in progress will be described.
Standard therapy is indicated for some children with HCV but the majority should await approval of DAAs. An algorithm for management and treatment of subjects <18 years of age at the present time is provided.
KeywordsHepatitis C Viral hepatitis Pediatric liver disease Direct acting antivirals Pegylated interferon and ribavirin Epidemiology of HCV in children
Compliance with Ethical Standards
Conflict of Interest
Kathleen B. Schwarz reports grants from Gilead, grants from Roche/Genentech, and personal fees from Up to Date, outside the submitted work.
Wikrom Karnsakul has had a relationship with Gilead as a sponsor for an Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children with Genotype 2 or 3 Chronic HCV Infection and a Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination in Adolescents and Children with Chronic HCV-Infection and a Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Chronic Hepatitis C Infection Trials.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.• Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr. 2016;28:93–100. doi: 10.1097/MOP.0000000000000313. This regimen could be considered in many children who DAAs are not yet available
- 8.• El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol. 2013;28:7880–8. doi: 10.3748/wjg.v19.i44.7880. While no specific treatment is available during pregnancy or at the time of delivery to prevent the vertical infection, El-Shabrawi et al pointed out the global economic and emotional burden of HCV infection for children, families, and countries
- 11.Koneru A, Nelson N, Hariri S, Canary L, Sanders KJ, Maxwell JF, et al. Increased hepatitis C virus (HCV) detection in women of childbearing age and potential risk for vertical transmission—United States and Kentucky, 2011–2014. MMWR Morb Mortal Wkly Rep. 2016;65:705–10. doi:10.15585/mmwr.mm6528a2Google Scholar
- 12.Mast EE, Hwang LY, Seto DS, Nolte FS, Nainan OV, Wurtzel H, Alter MJ, et al. Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy. J Infect Dis. 2005;192(11):1880-9. Epub 2005 Oct 28.Google Scholar
- 13.• Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59(6):765–73. doi:10.1093cid/ciu447 Benova et al performed a thorough review and meta-analysis on vertical transmission of hepatitis C virus. This review emphasizes certain risk factors which promote the vertical transmission as a major mode for HCV infection in children Google Scholar
- 14.Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, Pereda-Perez A, Alberola-Cuñat V, López-Hontangas JL, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol. 2015;194:173-7. doi: 10.1016/j.ejogrb.2015.09.009. Epub 2015 Sep 11
- 24.Mousa SM, El-Ghamrawy MK, Gouda H, Khorshied M, El-Salam Ahmed DA, Shiba H. Prevalence of hepatitis C among Egyptian children with sickle cell disease and the role of IL28b gene polymorphisms in spontaneous viral clearance. Mediterr J Hematol Infect Dis. 2016;8, e2016007. doi: 10.4084/MJHID.2016.007.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med. 1999;341:866–70. doi: 10.1056/NEJM199909163411202.CrossRefPubMedGoogle Scholar
- 28.Valva P, Casciato P, Lezama C, Galoppo M, Gadano A, Galdame O, et al. Serum apoptosis markers related to liver damage in chronic hepatitis C: sFas as a marker of advanced fibrosis in children and adults while M30 of severe steatosis only in children. PLoS One. 2013;8, e53519. doi: 10.1371/journal.pone.0053519.CrossRefPubMedPubMedCentralGoogle Scholar
- 30.•European Paediatric HIVHCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. AIDS. 2017;31(1):127–35. doi: 10.1097/QAD.0000000000001285. One of the risk factors is HIV/HCV co-infection and this was extensively reported by European Paediatric HIV/HCV study group with progressive liver disease among this vertically acquired HCVinfected children and young adults CrossRefGoogle Scholar
- 33.Roy A, Wang C, Li C, Lu L, Torbenson M, Hagedorn CH, et al. Phenotypic and genotypic differences between a child with vertically acquired severe hepatitis C liver disease and his mother. J Pediatr Gastroenterol Nutr. 2012;54:567–9. doi: 10.1097/MPG.0b013e318229d96f.CrossRefPubMedPubMedCentralGoogle Scholar
- 34.Abdelaziz DH, Elhosseiny NM, Khaleel SA, Sabry NA, Attia AS, El-Sayed MH. Association between combined presence of hepatitis C virus and polymorphisms in different genes with toxicities of methotrexate and 6-mercaptopurine in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2016;63:1539–45. doi: 10.1002/pbc.26045.CrossRefPubMedGoogle Scholar
- 37.•• Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, et al. NASPGHAN practice guidelines: diagnosis and management of hepatitis C infection in infants, children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54:838–55. doi: 10.1097/MPG.0b013e318258328d. These two papers focus on pediatric aspects of HCV infection in children. The work from Mack et al in 2012 discussed the guideline which details the epidemiology and natural history of HCV infection in children, the diagnostic workup, monitoring and treatment of disease, and provides an update on future treatment options and areas of research
- 38.• Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:961–7. doi: 10.1093/cid/cis1031. Despite the promising DAAs regimens, the current cost is high and may not be available for children in developing countries. A systematic review and meta-analysis conducted by Druyts et al indicates effectiveness and safety in treating HCV-infected children with peg-IFN alfa-2a or peg-IFN alfa-2b plus ribavirin
- 39.Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, et al. Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011;140:450-458.e1. doi: 10.1053/j.gastro.2010.10.047
- 40.Jonas MM, Balistreri W, Gonzalez-Peralta RP, Haber B, Lobritto S, Mohan P, et al. Pegylated interferon for chronic hepatitis C in children affects growth and body composition: results from the pediatric study of hepatitis C (PEDS-C) trial. Hepatology. 2012;56:523–31. doi: 10.1097/MPG.0b013e318185998f.CrossRefPubMedPubMedCentralGoogle Scholar
- 42.Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61:730–40. doi: 10.1093/cid/civ396.CrossRefPubMedPubMedCentralGoogle Scholar
- 43.Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62:25–30. doi: 10.1002/hep.27890.CrossRefPubMedGoogle Scholar
- 45.•• Balistreri WF, Murray KF, Rosenthal P, Bansal S, Chuan-Hao L, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology. 2016. doi: 10.1002/hep.28995. The recently published phase 2, multi-center, open-label study to evaluate the efficacy and safety of ledipasvir-sofosbuvir in adolescents with chronic HCV genotype 1 infection is a breakthrough in pediatric hepatology field. This study has blazed a trail to a safe, stepwise evaluation of DAAs as all-oral DAAs regimens for the pediatric population PubMedGoogle Scholar